Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently
under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic …

Infection with Mycobacterium tuberculosis (Mtb) leading to tuberculosis (TB) disease
continues to be a major global health challenge. Critical barriers, including but not limited to …

Bedaquiline is a diarylquinoline antimycobacterial drug and a key component of several
regimens in clinical development for the treatment of tuberculosis (TB) but with ongoing …

Tuberculosis (TB) remains one of the leading causes of death by a communicable agent,
infecting up to one-quarter of the world's population, predominantly in disadvantaged …

Advances in clinical trial design: Weaving tomorrow’s TB treatments | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

The past years have witnessed concerted efforts across the respiratory community to
establish more relevant in vitro preclinical tools for pulmonary research [1-3]. A strong …